Introduction
Materials and methods
Literature search strategy
Selection and exclusion criteria
Data extraction
Statistical analysis
False-positive report probability (FPRP) analysis
Results
Process of study selection and description of qualified studies
First author | Year | Country | Ethnicity | Genotyping | Source of | Genotype distribution | HWE | NOS | Cancer | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
methods | control | Case | Control | P-value | types | |||||||||
13 Studies for H19 gene rs2107425 C/T polymorphism
| ||||||||||||||
CC | CT | TT | CC | CT | TT | |||||||||
Verhaegh | 2008 | Netherlands | Caucasian | PCR-RFLP | PB | 92 | 65 | 20 | 89 | 96 | 19 | 0.3402 | 9 | BLC |
Song HL | 2009 | Mixed | Caucasian | TaqMan | PB | 2619 | 2192 | 555 | 4029 | 3667 | 842 | 0.8565 | 9 | OC |
Quaye | 2009 | Mixed | Caucasian | TaqMan | PB | 767 | 544 | 149 | 1118 | 1098 | 247 | 0.3449 | 6 | OC |
Barnholtz | 2010 | USA | African | Illumina | PB | 161 | 390 | 186 | 170 | 339 | 149 | 0.4199 | 7 | BC |
Barnholtz | 2010 | USA | Caucasian | Illumina | PB | 604 | 516 | 105 | 521 | 478 | 119 | 0.5489 | 7 | BC |
Butt S | 2012 | Sweden | Caucasian | Mass Array | PB | 361 | 250 | 68 | 668 | 573 | 145 | 0.1816 | 8 | BC |
Gong WJ | 2016 | China | Asian | Sequenom | HB | 181 | 235 | 63 | 79 | 96 | 28 | 0.8920 | 6 | LC |
Yin ZH | 2018 | China | Asian | Illumina | HB | 161 | 266 | 129 | 140 | 185 | 70 | 0.5129 | 8 | LC |
Wu | 2019 | China | Asian | TaqMan | HB | 134 | 185 | 40 | 422 | 560 | 208 | 0.3451 | 8 | HCC |
Huang MC | 2019 | China | Asian | PCR | PB | 88 | 107 | 38 | 109 | 155 | 48 | 0.5590 | 8 | CC |
Yang PJ | 2019 | China | Asian | RT-PCR | HB | 152 | 213 | 66 | 171 | 190 | 70 | 0.1636 | 7 | UCC |
Ghapanchi | 2020 | Iran | Asian | ARMS-PCR | PB | 79 | 94 | 27 | 74 | 101 | 25 | 0.2911 | 8 | OSCC |
Khalil | 2022 | Egypt | African | QIAamp | HB | 25 | 32 | 13 | 20 | 9 | 1 | 0.9919 | 6 | CRC |
30 Studies for H19 gene rs217727 G/A polymorphism
| ||||||||||||||
GG | GA | AA | GG | GA | AA | |||||||||
Verhaegh | 2008 | Netherlands | Caucasian | PCR-RFLP | PB | 114 | 59 | 4 | 115 | 80 | 9 | 0.2880 | 9 | BLC |
Yang C | 2015 | Netherlands | Caucasian | TaqMan | HB | 160 | 252 | 88 | 193 | 244 | 63 | 0.2957 | 8 | GC |
Li SW | 2016 | China | Asian | TaqMan | HB | 480 | 514 | 153 | 456 | 570 | 177 | 0.9585 | 9 | CRC |
Hua QH | 2016 | China | Asian | TaqMan | HB | 431 | 467 | 148 | 573 | 665 | 156 | 0.0740 | 7 | BLC |
Xia Z | 2016 | China | Asian | CRS-RFLP | PB | 160 | 156 | 148 | 139 | 212 | 116 | 0.0521 | 9 | BC |
Jin TB | 2016 | China | Asian | Mass Array | PB | 117 | 103 | 26 | 169 | 99 | 16 | 0.7651 | 9 | CC |
Guo QY | 2017 | China | Asian | Illumina | HB | 101 | 181 | 80 | 252 | 348 | 137 | 0.3840 | 8 | OSCC |
Hassanzarei | 2017 | China | Asian | PCR-RFLP | HB | 71 | 132 | 27 | 125 | 113 | 2 | 0.0000* | 7 | BC |
He TD | 2017 | Iran | Asian | TaqMan | HB | 79 | 102 | 12 | 195 | 165 | 23 | 0.1207 | 6 | Osteosarcoma |
Hu PH | 2017 | China | Asian | TaqMan | HB | 133 | 200 | 83 | 128 | 196 | 92 | 0.3022 | 8 | PC |
Lin YX | 2017 | China | Asian | G0104K | HB | 403 | 471 | 131 | 465 | 450 | 105 | 0.8007 | 8 | BC |
Li LL | 2018 | China | Asian | TaqMan | HB | 210 | 250 | 95 | 246 | 305 | 67 | 0.0542 | 8 | LC |
Yin ZH | 2018 | China | Asian | Illumina | HB | 204 | 264 | 88 | 165 | 172 | 58 | 0.2319 | 8 | LC |
Yuan ZY | 2018 | China | Asian | Mass Array | PB | 186 | 194 | 51 | 488 | 423 | 73 | 0.1511 | 7 | OSCC |
Cui P | 2018 | China | Asian | TaqMan | PB | 611 | 692 | 185 | 685 | 773 | 217 | 0.9628 | 7 | BC |
GG | GA | AA | GG | GA | AA | |||||||||
Abdollahzadeh | 2018 | China | Asian | RFLP-PCR | HB | 116 | 29 | 5 | 86 | 14 | 0 | 0.4516 | 8 | BC |
Hu C | 2019 | Iran | Asian | TaqMan | HB | 186 | 164 | 43 | 382 | 342 | 86 | 0.4696 | 7 | Neuroblastoma |
Li Z | 2019 | China | Asian | TaqMan | HB | 51 | 140 | 9 | 84 | 90 | 26 | 0.8061 | 8 | BLC |
Mohammad | 2019 | China | Asian | ARMS-PCR | HB | 79 | 30 | 2 | 64 | 54 | 12 | 0.9003 | 7 | BC |
Wang GZ | 2019 | Iran | Asian | TaqMan | HB | 162 | 277 | 125 | 493 | 751 | 291 | 0.8676 | 6 | LC |
Wu | 2019 | China | Asian | TaqMan | HB | 154 | 170 | 35 | 495 | 539 | 156 | 0.6265 | 8 | HCC |
Wei MR | 2019 | China | Asian | TaqMan | HB | 88 | 72 | 65 | 63 | 44 | 93 | 0.0000* | 7 | GC |
Huang MC | 2019 | China | Asian | PCR | PB | 102 | 103 | 28 | 135 | 139 | 39 | 0.7289 | 8 | CC |
Yang PJ | 2019 | China | Asian | RT-PCR | HB | 185 | 202 | 44 | 191 | 188 | 52 | 0.5845 | 7 | UCC |
Cao Q | 2020 | China | Asian | RT-PCR | HB | 343 | 550 | 201 | 350 | 494 | 183 | 0.7042 | 8 | RCC |
Ghapanchi | 2020 | China | Asian | ARMS-PCR | PB | 110 | 75 | 15 | 133 | 64 | 3 | 0.1259 | 8 | OSCC |
Deng YJ | 2020 | Iran | Asian | Mass Array | HB | 254 | 278 | 73 | 557 | 591 | 152 | 0.8018 | 7 | Glioma |
Tan TB | 2020 | China | Asian | TaqMan | HB | 126 | 68 | 19 | 438 | 410 | 109 | 0.3811 | 8 | Hepatoblastoma |
Li WY | 2021 | China | Asian | TaqMan | PB | 177 | 130 | 48 | 486 | 469 | 113 | 0.9925 | 7 | Wilms |
Pei JS | 2021 | China | Asian | RT-PCR | PB | 111 | 120 | 35 | 114 | 120 | 32 | 0.9610 | 7 | Leukemia |
26 Studies for H19 gene rs2839698 G/A polymorphism
| ||||||||||||||
GG | GA | AA | GG | GA | AA | |||||||||
Verhaegh | 2008 | Netherlands | Caucasian | PCR-RFLP | PB | 54 | 74 | 49 | 52 | 109 | 43 | 0.3125 | 9 | BLC |
Yang C | 2015 | China | Asian | TaqMan | HB | 250 | 195 | 55 | 284 | 178 | 38 | 0.1754 | 8 | GC |
Li SW | 2016 | China | Asian | TaqMan | HB | 583 | 462 | 102 | 666 | 462 | 75 | 0.6665 | 9 | CRC |
Hua QH | 2016 | China | Asian | TaqMan | HB | 552 | 418 | 79 | 729 | 565 | 103 | 0.6510 | 7 | BLC |
Gong WJ | 2016 | China | Asian | TaqMan | HB | 237 | 220 | 39 | 99 | 80 | 27 | 0.0982 | 6 | LC |
Guo QY | 2017 | China | Asian | Illumina | HB | 133 | 171 | 58 | 244 | 377 | 120 | 0.2021 | 8 | ORC |
Hassanzarei | 2017 | China | Asian | PCR-RFLP | HB | 0 | 64 | 166 | 0 | 18 | 222 | 0.5461 | 7 | BC |
He TD | 2017 | Iran | Asian | TaqMan | HB | 83 | 98 | 12 | 178 | 175 | 30 | 0.1462 | 6 | Osteosarcoma |
Lin YX | 2017 | China | Asian | G0104K | HB | 452 | 440 | 113 | 484 | 432 | 104 | 0.5998 | 8 | BC |
Yang ML | 2018 | China | Asian | KASP | HB | 215 | 211 | 40 | 245 | 185 | 32 | 0.7141 | 8 | HCC |
Cui P | 2018 | China | Asian | TaqMan | PB | 801 | 568 | 122 | 875 | 673 | 129 | 0.9793 | 7 | BC |
Hu C | 2019 | China | Asian | TaqMan | HB | 179 | 175 | 39 | 365 | 373 | 72 | 0.0896 | 7 | Neuroblastoma |
Mohammad | 2019 | China | Asian | ARMS-PCR | HB | 15 | 57 | 39 | 53 | 55 | 22 | 0.2410 | 7 | BC |
Wang GZ | 2019 | China | Asian | TaqMan | HB | 277 | 225 | 61 | 712 | 645 | 175 | 0.1173 | 6 | LC |
Wu | 2019 | China | Asian | TaqMan | HB | 140 | 178 | 41 | 532 | 524 | 134 | 0.7718 | 8 | HCC |
Wei MR | 2019 | Iran | Asian | TaqMan | HB | 90 | 68 | 67 | 88 | 78 | 34 | 0.0248* | 7 | GC |
Huang MC | 2019 | China | Asian | PCR | PB | 115 | 99 | 20 | 154 | 134 | 30 | 0.9132 | 8 | CC |
GG | GA | AA | GG | GA | AA | |||||||||
Yang PJ | 2019 | China | Asian | RT-PCR | HB | 206 | 170 | 55 | 192 | 184 | 55 | 0.2973 | 7 | UCC |
Cao Q | 2020 | Iran | Asian | RT-PCR | HB | 516 | 435 | 76 | 615 | 425 | 54 | 0.0732 | 8 | RCC |
Deng YJ | 2020 | China | Asian | PCR | HB | 134 | 140 | 40 | 154 | 211 | 72 | 0.0581 | 7 | Glioma |
Yu BQ | 2020 | China | Asian | Mass Array | HB | 311 | 240 | 54 | 675 | 504 | 121 | 0.9847 | 7 | CRC |
Zhang HB | 2020 | China | Asian | Mass Array | HB | 70 | 93 | 38 | 92 | 88 | 16 | 0.4260 | 6 | OC |
Tan TB | 2020 | China | Asian | TaqMan | PB | 102 | 78 | 33 | 439 | 424 | 94 | 0.5679 | 8 | Hepatoblastoma |
Li WY | 2021 | China | Asian | TaqMan | HB | 174 | 127 | 54 | 488 | 480 | 100 | 0.2453 | 7 | Wilms |
Pei JS | 2021 | China | Asian | RT-PCR | PB | 91 | 131 | 44 | 119 | 117 | 30 | 0.8781 | 7 | Leukemia |
Zhang JZ | 2021 | Iran | Asian | PCR-RFLP | HB | 192 | 244 | 137 | 351 | 248 | 89 | 0.0000* | 8 | Lymphoma |
10 Studies for H19 gene rs3741219 A/G polymorphism
| ||||||||||||||
AA | AG | GG | AA | AG | GG | |||||||||
Yang C | 2015 | China | Asian | TaqMan | HB | 260 | 187 | 53 | 268 | 189 | 43 | 0.2446 | 8 | GC |
Hassanzarei | 2017 | Iran | Asian | PCR-RFLP | HB | 63 | 126 | 42 | 109 | 102 | 29 | 0.4979 | 7 | BC |
Cui P | 2018 | China | Asian | TaqMan | PB | 782 | 582 | 127 | 832 | 706 | 139 | 0.5291 | 7 | BC |
Abdollahzadeh | 2018 | Iran | Asian | RFLP-PCR | HB | 119 | 24 | 7 | 80 | 17 | 3 | 0.0993 | 8 | BC |
Wu | 2019 | China | Asian | TaqMan | HB | 129 | 182 | 48 | 517 | 536 | 137 | 0.9140 | 8 | HCC |
Yang PJ | 2019 | China | Asian | RT-PCR | HB | 192 | 181 | 58 | 185 | 190 | 56 | 0.5121 | 7 | UCC |
Huang MC | 2019 | China | Asian | PCR | PB | 112 | 100 | 21 | 152 | 130 | 32 | 0.5906 | 8 | CC |
Cao Q | 2020 | China | Asian | RT-PCR | HB | 567 | 416 | 111 | 552 | 389 | 86 | 0.1400 | 8 | RCC |
Deng YJ | 2020 | China | Asian | Mass Array | HB | 439 | 107 | 59 | 651 | 520 | 129 | 0.0956 | 7 | Glioma |
Zhang HB | 2020 | China | Asian | Mass Array | HB | 190 | 1 | 20 | 186 | 0 | 9 | 0.0000* | 6 | OC |
12 Studies for H19 gene rs3024270 C/G polymorphism
| ||||||||||||||
CC | CG | GG | CC | CG | GG | |||||||||
Hua QH | 2016 | China | Asian | TaqMan | HB | 174 | 527 | 346 | 260 | 688 | 447 | 0.8686 | 7 | BLC |
Li SW | 2016 | China | Asian | TaqMan | HB | 385 | 527 | 235 | 420 | 582 | 201 | 0.9794 | 9 | CRC |
Guo QY | 2017 | China | Asian | Illumina | HB | 75 | 183 | 104 | 145 | 350 | 245 | 0.3213 | 8 | OSCC |
He TD | 2017 | China | Asian | TaqMan | HB | 17 | 91 | 85 | 31 | 179 | 173 | 0.1014 | 6 | Osteosarcoma |
Yang ML | 2018 | China | Asian | KASP | HB | 95 | 225 | 151 | 81 | 215 | 170 | 0.3609 | 8 | HCC |
Hu C | 2019 | China | Asian | TaqMan | HB | 99 | 203 | 91 | 213 | 424 | 173 | 0.1591 | 7 | Neuroblastoma |
Li Z | 2019 | China | Asian | TaqMan | HB | 16 | 101 | 83 | 22 | 97 | 81 | 0.3771 | 8 | BLC |
Huang MC | 2019 | China | Asian | PCR | PB | 51 | 120 | 60 | 71 | 150 | 95 | 0.4225 | 8 | CC |
Wu | 2019 | China | Asian | TaqMan | HB | 87 | 187 | 85 | 334 | 593 | 263 | 0.9945 | 8 | HCC |
Yang PJ | 2019 | China | Asian | RT-PCR | HB | 114 | 210 | 107 | 120 | 208 | 103 | 0.4894 | 7 | UCC |
Tan TB | 2020 | China | Asian | TaqMan | PB | 50 | 87 | 76 | 264 | 489 | 204 | 0.4216 | 8 | Hepatoblastoma |
CC | CG | GG | CC | CG | GG | |||||||||
Li WY | 2021 | China | Asian | TaqMan | HB | 120 | 141 | 94 | 290 | 556 | 222 | 0.1376 | 7 | Wilms |
4 Studies for H19 gene rs3741216 A/T polymorphism
| ||||||||||||||
AA | AT | TT | AA | AT | TT | |||||||||
Yang C | 2015 | China | Asian | TaqMan | HB | 380 | 102 | 18 | 379 | 109 | 12 | 0.2210 | 8 | GC |
Hassanzarei | 2017 | Iran | Asian | PCR-RFLP | HB | 0 | 26 | 204 | 0 | 65 | 26 | 0.0150* | 7 | BC |
Wei MR | 2019 | China | Asian | TaqMan | HB | 79 | 91 | 55 | 70 | 78 | 52 | 0.0025* | 7 | GC |
Cao Q | 2020 | China | Asian | RT-PCR | HB | 791 | 255 | 48 | 718 | 264 | 35 | 0.0834 | 8 | RCC |
Correlation between rs2107425 C/T polymorphism and cancer risk
Locus | No. | Allele | Homozygote | Heterozygote | Dominant | Recessive | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
OR (95%CI) P | I2 (%) | OR (95%CI) P | I2 (%) | OR (95%CI) P | I2 (%) | OR (95%CI) P | I2 (%) | OR (95%CI) P | I2 (%) | ||
rs2107425C/T | |||||||||||
Total | 13 | 0.98 (0.91, 1.06) 0.595 | 68.0 | 1.01 (0.88, 1.17) 0.846 | 53.9 | 0.96 (0.85, 1.07) 0.438 | 66.8 | 0.97 (0.87, 1.08) 0.543 | 69.2 | 0.98 (0.91, 1.06) 0.651 | 43.2 |
Ethnicity | |||||||||||
Caucasian | 5 | 0.91 (0.85, 0.97) 0.006* | 46.2 | 0.94 (0.85, 1.04) 0.226 | 6.4 | 0.83 (0.73, 0.94) 0.003* | 67.0 | 0.85 (0.76, 0.94) 0.003* | 62.3 | 1.01 (0.93, 1.11) 0.813 | 5.1 |
Asian | 6 | 1.02 (0.89, 1.16) 0.799 | 54.9 | 1.00 (0.75, 1.35) 0.978 | 60.6 | 1.08 (0.95, 1.23) 0.249 | 0.0 | 1.06 (0.92, 1.22) 0.453 | 24.6 | 0.96 (0.82, 1.13) 0.649 | 60.1 |
African | 2 | 1.77 (0.66, 4.76) 0.255 | 85.8 | 2.82 (0.39, 20.15) 0.302 | 72.5 | 1.64 (0.74, 3.63) 0.224 | 65.5 | 1.93 (0.69, 5.38) 0.208 | 79.7 | 1.21 (0.95, 1.54) 0.132 | 62.8 |
Source of control | |||||||||||
PB | 8 | 0.94 (0.87, 1.00) 0.067 | 50.1 | 0.97 (0.87, 1.08) 0.529 | 16.8 | 0.87 (0.78, 0.97) 0.016* | 61.6 | 0.89 (0.80, 0.98) 0.024 | 60.5 | 1.03 (0.95, 1.12) 0.519 | 0.0 |
HB | 5 | 1.13 (0.90, 1.52) 0.313 | 79.3 | 1.11 (0.69, 1.77) 0.664 | 76.8 | 1.18 (1.00, 1.39) 0.049* | 18.4 | 1.20 (0.94, 1.53) 0.143 | 63.3 | 0.96 (0.80, 1.15) 0.475 | 74.1 |
NOS scores | |||||||||||
N1 | 6 | 1.02 (0.88, 1.20) 0.761 | 78.9 | 1.00 (0.79, 1.28) 0.977 | 59.6 | 1.06 (0.83, 1.35) 0.658 | 81.3 | 1.07 (0.84, 1.35) 0.593 | 82.3 | 1.02 (0.90, 1.16) 0.778 | 7.3 |
N2 | 7 | 0.96 (0.87, 1.06) 0.414 | 55.6 | 0.98 (0.80, 1.20) 0.839 | 55.4 | 0.93 (0.82, 1.03) 0.129 | 36.1 | 0.93 (0.83, 1.04) 0.197 | 43.0 | 0.97 (0.89, 1.07) 0.568 | 62.3 |
Sample size | |||||||||||
S1 | 7 | 1.08 (0.92, 1.26) 0.344 | 60.1 | 1.17 (0.91, 1.49) 0.221 | 28.6 | 1.04 (0.84, 1.31) 0.708 | 56.1 | 1.08 (0.86, 1.36) 0.492 | 62.4 | 1.15 (0.96, 1.37) 0.215 | 3.3 |
S2 | 6 | 0.93 (0.85, 1.06) 0.061 | 67.5 | 0.91 (0.76, 1.07) 0.249 | 63.7 | 0.91 (0.80, 1.03) 0.115 | 71.8 | 0.90 (0.80, 1.01) 0.070 | 69.7 | 0.99 (0.91, 1.08) 0.830 | 62.2 |
Cancer type | |||||||||||
OC | 2 | 0.92 (0.80, 1.05) 0.196 | 82.5 | 0.98 (0.86, 1.11) 0.698 | 18.4 | 0.82 (0.65, 1.04) 0.102 | 89.2 | 0.85 (0.68, 1.05) 0.127 | 88.6 | 1.05 (0.95, 1.16) 0.371 | 0.0 |
BC | 3 | 0.96 (0.82, 1.13) 0.624 | 74.6 | 0.95 (0.69, 1.32) 0.774 | 71.6 | 0.96 (0.78, 1.17) 0.661 | 66.9 | 0.96 (0.77, 1.19) 0.683 | 73.0 | 0.97 (0.83, 1.13) 0.681 | 51.3 |
LC | 2 | 1.15 (0.92, 1.44) 0.226 | 56.0 | 1.30 (0.81, 2.09) 0.280 | 65.1 | 1.17 (0.94, 1.47) 0.168 | 0.0 | 1.21 (0.95, 1.54) 0.119 | 21.0 | 1.24 (0.95, 1.63) 0.114 | 43.7 |
rs217727G/A | |||||||||||
Total | 30 | 1.06 (0.99, 1.14) 0.097 | 77.6 | 1.12 (0.97, 1.30) 0.109 | 70.2 | 1.07 (0.97, 1.17) 0.182 | 70.2 | 1.08 (0.98, 1.19) 0.109 | 74.4 | 1.09 (0.96, 1.24) 0.201 | 70.1 |
Ethnicity | |||||||||||
Caucasian | 1 | 0.74 (0.52, 1.05) 0.089 | 0.49 (0.13, 1.50) 0.192 | 0.74 (0.49, 1.14) 0.172 | 0.71 (0.47, 1.08) 0.111 | 0.50 (0.15, 1.66) 0.257 | |||||
Asian | 29 | 1.07 (1.00, 1.15) 0.060 | 77.6 | 1.14 (0.98, 1.31) 0.082 | 70.6 | 1.08 (0.98, 1.18) 0.130 | 70.5 | 1.09 (0.99, 1.20) 0.070 | 74.5 | 1.10 (0.96, 1.025) 0.165 | 70.6 |
Source of control | |||||||||||
PB | 9 | 1.06 (0.91, 1.24) 0.460 | 79.2 | 1.18 (0.87, 1.06) 0.286 | 70.6 | 0.96 (0.79, 1.17) 0.689 | 73.9 | 1.01 (0.83, 1.24) 0.903 | 77.4 | 1.21 (0.94, 1.57) 0.143 | 63.9. |
HB | 21 | 1.07 (0.98, 1.16) 0.144 | 77.9 | 1.11 (0.94, 1.31) 0.236 | 71.5 | 1.11 (1.00, 1.23) 0.055 | 68.7 | 1.11 (1.00, 1.24) 0.063 | 73.7 | 1.05 (0.90, 1.23) 0.567 | 73.0 |
NOS scores | |||||||||||
N1 | 11 | 1.03 (0.89, 1.19) 0.068 | 84.7 | 1.12 (0.85, 1.47) 0.441 | 77.9 | 1.05 (0.90, 1.22) 0.558 | 70.7 | 1.04 (0.88, 1.23) 0.063 | 78.8 | 1.10 (0.94, 1.27) 0.529 | 78.1 |
N2 | 19 | 1.08 (0.99, 1.17) 0.717 | 71.4 | 1.13 (0.96, 1.34) 0.145 | 65.4 | 1.08 (0.95, 1.22) 0.229 | 71.3 | 1.10 (0.98, 1.24) 0.103 | 72.5 | 1.09 (0.84, 1.41) 0.240 | 64.7 |
Sample size | |||||||||||
S1 | 14 | 1.08 (0.90, 1.29) 0.432 | 84.3 | 1.11 (0.76, 1.60) 0.595 | 76.5 | 1.15 (0.92, 1.44) 0.215 | 77.9 | 1.14 (0.91, 1.42) 0.272 | 81.1 | 1.03 (0.68, 1.40) 0.873 | 79.2 |
S2 | 16 | 1.06 (0.99, 1.13) 0.094 | 67.8 | 1.17 (1.02, 1.33) 0.022* | 61.9 | 1.02 (0.94, 1.11) 0.636 | 57.7 | 1.05 (0.96, 1.15) 0.290 | 65.1 | 1.14 (1.03, 1.28) 0.015* | 52.0 |
Cancer type | |||||||||||
BLC | 3 | 1.01 (0.82, 1.25) 0.923 | 56.8 | 0.80 (0.40, 1.62) 0.538 | 64 | 1.20 (0.64, 2.23) 0.574 | 90.1 | 1.13 (0.68, 1.88) 0.629 | 85.9 | 0.63 (0.22, 1.80) 0.390 | 85.1 |
GC | 2 | 0.88 (0.42, 1.84) 0.738 | 95.1 | 0.92 (0.28, 3.04) 0.896 | 93.8 | 1.23 (0.97, 1.56) 0.093 | 0.0 | 1.00 (0.54, 1.84) 0.993 | 84.7 | 0.84 (0.27, 2.59) 0.756 | 94.5 |
BC | 6 | 1.13 (0.87, 1.46) 0.351 | 89.5 | 1.33 (0.79, 2.25) 0.284 | 83.8 | 1.02 (0.74, 1.40) 0.908 | 85.5 | 1.09 (0.79, 1.52) 0.594 | 88.1 | 1.33 (0.85, 2.08) 0.211 | 80.8 |
CC | 2 | 1.22 (0.78, 1.90) 0.379 | 82.4 | 1.46 (0.60, 3.55) 0.399 | 76.3 | 1.21 (0.80, 1.84) 0.364 | 62.5 | 1.26 (0.76, 2.07) 0.371 | 76.3 | 1.34 (0.66, 2.72) 0.416 | 65.8 |
OSCC | 3 | 1.31 (1.14, 1.50) 0.000* | 24.8 | 1.89 (1.18, 3.00) 0.008* | 57.7 | 1.27 (1.07, 1.50) 0.006* | 0.0 | 1.36 (1.16, 1.60) 0.000* | 0.0 | 1.67 (1.04, 2.68) 0.035* | 64.6 |
Cancer type | |||||||||||
LC | 3 | 1.16 (1.06, 1.27) 0.002* | 0.0 | 1.38 (1.14, 1.67) 0.001* | 0.0 | 1.09 (0.95, 1.26) 0.219 | 0.0 | 1.16 (1.01, 1.33) 0.031 | 0.0 | 1.31 (1.03, 1.66) 0.028* | 44.7 |
HCC | 2 | 0.79 (0.60, 1.05) 0.100 | 71.7 | 0.68 (0.49, 0.93) 0.017* | 0.0 | 0.77 (0.44, 1.34) 0.359 | 86.3 | 0.75 (0.47, 1.21) 0.237 | 83.8 | 0.73 (0.54, 1.00) 0.048* | 0.0 |
rs2839698G/A | |||||||||||
Total | 26 | 1.10 (1.01, 1.20) 0.039* | 82.8 | 1.29 (1.09, 1.52) 0.003* | 74.7 | 1.06 (0.97,1.17) 0.215 | 68.5 | 1.11 (1.01, 1.23) 0.036* | 75.4 | 1.18 (1.01, 1.39) 0.042* | 76.6 |
Ethnicity | |||||||||||
Caucasian | 1 | 1.03 (0.78, 1.37) 0.827 | 1.10 (0.63, 1.92) 0.745 | 0.65 (0.40, 2.06) 0.084 | 0.78 (0.50, 1.22) 0.276 | 1.43 (0.90, 2.30) 0.134 | |||||
Asian | 25 | 1.10 (1.00, 1.21) 0.041* | 83.5 | 1.30 (1.09, 1.54) 0.003* | 75.7 | 1.07 (0.98, 1.18) 0.138 | 68.2 | 1.12 (1.02, 1.24) 0.024* | 75.9 | 1.17 (0.99, 1.39) 0.060 | 74.4 |
Source of control | |||||||||||
PB | 5 | 1.06 (0.94, 1.21) 0.344 | 45.6 | 1.22 (0.95, 1.57) 0.122 | 34.4 | 0.94 (0.76,1.16) 0.560 | 55.2 | 1.00 (1.025,1.21) 0.983 | 51.3 | 1.28 (1.02, 1.59) 0.032* | 27.9 |
HB | 21 | 1.10 (0.99, 1.23) 0.072 | 85.3 | 1.30 (1.07, 1.59) 0.009* | 78.5 | 1.09 (0.98,1.21) 0.106 | 69.5 | 1.14 (1.02, 1.28) 0.025* | 77.6 | 1.16 (0.95, 1.04) 0.142 | 80.2 |
NOS scores | |||||||||||
N1 | 14 | 1.01 (0.90, 1.15) 0.830 | 76.6 | 1.14 (0.91, 1.43) 0.251 | 73.2 | 0.99 (0.88,1.11) 0.843 | 60.3 | 1.02 (0.91, 1.16) 0.704 | 66.4 | 1.02 (0.80, 1.31) 0.881 | 81.1 |
N2 | 12 | 1.20 (1.08, 1.34) 0.001* | 82.0 | 1.46 (1.17, 1.81) 0.001* | 69.4 | 1.14 (1.00, 1.29) 0.052 | 65.7 | 1.20 (1.05, 1.38) 0.010* | 73.4 | 1.39 (1.17, 1.65) 0.000* | 54.8 |
Sample size | |||||||||||
S1 | 10 | 1.07 (0.87, 1.32) 0.510 | 86.5 | 1.33 (0.92, 1.92) 0.134 | 79.6 | 1.11 (0.91,1.35) 0.317 | 67.9 | 1.17 (0.95,1.45) 0.138 | 75.3 | 1.08 (0.74, 1.57) 0.692 | 84.5 |
S2 | 14 | 1.11 (1.01, 1.21) 0.030* | 79.7 | 1.28 (1.07, 1.53) 0.006* | 71.6 | 1.04 (0.94, 1.16) 0.425 | 91.0 | 1.09 (0.97, 1.22) 0.137 | 77.2 | 1.25 (1.09, 1.45) 0.002* | 60.7 |
Cancer type | |||||||||||
BLC | 2 | 1.00 (0.89, 1.12) 0.992 | 0.0 | 1.03 (0.79, 1.36) 0.819 | 0.0 | 0.85 (0.59, 1.24) 0.405 | 58.0 | 0.96 (0.82, 1.13) 0.570 | 0.0 | 1.15 (0.84, 1.58) 0.379 | 28.0 |
GC | 2 | 1.33 (1.13, 1.56) 0.000* | 0.0 | 1.76 (1.26, 2.46) 0.001* | 0.0 | 1.07 (0.75, 1.54) 0.699 | 52.3 | 1.27 (1.03, 1.57) 0.024* | 0.0 | 1.74 (1.27, 2.40) 0.001* | 0.0 |
HCC | 3 | 1.15 (1.03, 1.29) 0.014* | 0.0 | 1.33 (1.03, 1.72) 0.027* | 0.0 | 1.12 (0.83, 1.51) 0.299 | 73.1 | 1.17 (0.95, 1.44) 0.136 | 45.4 | 1.27 (0.94, 1.73) 0.117 | 34.5 |
CRC | 2 | 0.98 (0.65, 1.48) 0.927 | 90.9 | 1.01 (0.42, 2.42) 0.981 | 90.0 | 0.96 (0.64, 1.42) 0.817 | 79.6 | 0.95 (0.59, 1.55) 0.842 | 87.8 | 1.06 (0.54, 2.07) 0.869 | 85.0 |
LC | 2 | 0.92 (0.81, 1.04) 0.178 | 0.0 | 0.78 (0.54, 1.13) 0.192 | 33.4 | 0.97 (0.78, 1.23) 0.822 | 31.0 | 0.93 (0.78, 1.09) 0.359 | 0.0 | 0.76 (0.47, 2.25) 0.283 | 63.4 |
BC | 4 | 0.96 (0.63, 1.45) 0.839 | 94.3 | 1.72 (0.88, 3.34) 0.111 | 89.3 | 1.28 (0.86, 1.90) 0.220 | 87.3 | 1.40 (0.91, 1.11) 0.132 | 90.7 | 0.91 (0.45, 1.83) 0.789 | 92.7 |
rs3741219 A/G | |||||||||||
Total | 10 | 1.07 (0.88, 1.30) 0.507 | 89.4 | 1.18 (0.94, 1.48) 0.154 | 61.8 | 0.97 (0.71, 1.33) 0.842 | 91.8 | 1.56 (0.79, 1.41) 0.709 | 91.8 | 1.14 (1.01, 1.29) 0.037* | 0.0 |
Ethnicity | |||||||||||
Asian | 10 | 1.07 (0.88, 1.30) 0.507 | 89.4 | 1.18 (0.94, 1.48) 0.154 | 61.8 | 0.97 (0.71, 1.33) 0.842 | 91.8 | 1.56 (0.79, 1.41) 0.709 | 91.8 | 1.14 (1.01, 1.29) 0.037* | 0.0 |
Source of control | |||||||||||
PB | 2 | 0.94 (0.85, 1.04) 0.253 | 0.0 | 0.96 (0.76, 1.22) 0.730 | 0.0 | 0.90 (0.79, 1.03) 0.126 | 0.0 | 0.91 (0.80, 1.04) 0.149 | 0.0 | 1.00 (0.80, 1.26) 0.978 | 0.0 |
HB | 8 | 1.11 (0.86, 1.45) 0.424 | 91.6 | 1.28 (0.96, 1.71) 0.100 | 67.6 | 0.98 (0.63, 1.54) 0.941 | 93.6 | 1.10 (0.74, 1.64) 0.625 | 93.6 | 1.20 (1.04, 1.39) 0.014 | 0.0 |
NOS scores | |||||||||||
N1 | 5 | 1.07 (0.74, 1.55) 0.726 | 94.2 | 1.19 (0.79, 1.79) 0.417 | 78.9 | 0.88 (0.46, 1.67) 0.691 | 95.4 | 1.04 (0.60, 1.79) 0.898 | 95.4 | 1.10 (0.94, 1.30) 0.235 | 0.0 |
N2 | 4 | 1.11 (1.02, 1.21) 0.015* | 20.0 | 1.26 (1.03, 1.53) 0.022* | 0.0 | 1.10 (0.97, 1.24) 0.131 | 0.0 | 1.12 (1.00, 1.26) 0.042* | 0.0 | 1.19 (0.98, 1.43) 0.038* | 29.3 |
Sample size | |||||||||||
S1 | 5 | 0.94 (0.73, 1.22) 0.119 | 76.2 | 1.44 (0.90, 2.29) 0.126 | 59.1 | 1.20 (0.82, 1.77) 0.348 | 67.4 | 1.32 (0.89, 1.95) 0.164 | 76.0 | 1.23 (0.96, 1.59) 0.107 | 21.8 |
S2 | 5 | 1.26 (0.94, 1.69) 0.642 | 93.3 | 1.07 (0.83, 1.37) 0.618 | 64.7 | 0.83 (0.53, 1.29) 0.399 | 95.5 | 0.88 (0.59, 1.31) 0.527 | 95.2 | 1.11 (0.97, 1.28) 0.137 | 0.0 |
Cancer type | |||||||||||
BC | 3 | 1.20 (0.78, 1.85) 0.405 | 87.2 | 1.51 (0.72, 3.18) 0.281 | 78.0 | 1.21 (0.65, 2.28) 0.546 | 87.8 | 1.27 (0.67, 2.40) 0.462 | 89.5 | 1.14 (0.91, 1.42) 0.258 | 23.9 |
rs3024270 C/G | |||||||||||
Total | 12 | 1.04 (0.97, 1.12) 0.261 | 45.0 | 1.12 (1.01, 1.24) 0.025* | 40.6 | 1.00 (0.91, 1.09) 0.926 | 34.1 | 1.03 (0.95, 1.12) 0.421 | 19.9 | 1.09 (0.95, 1.25) 0.228 | 65.3 |
Ethnicity | |||||||||||
Asian | 12 | 1.04 (0.97, 1.12) 0.261 | 45.0 | 1.12 (1.01, 1.24) 0.025* | 40.6 | 1.00 (0.91, 1.09) 0.926 | 34.1 | 1.03 (0.95, 1.12) 0.421 | 19.9 | 1.09 (0.95, 1.25) 0.228 | 65.3 |
Source of control | |||||||||||
PB | 2 | 1.16 (0.75, 1.80) 0.494 | 86.5 | 1.42 (1.05, 1.93) 0.025* | 84.2 | 1.01 (0.76, 1.35) 0.936 | 0.0 | 1.15 (0.88, 1.49) 0.309 | 0.0 | 1.30 (0.53, 3.21) 0.568 | 92.4 |
HB | 10 | 1.03 (0.98, 1.09) 0.289 | 6.9 | 1.09 (0.98, 1.21) 0.112 | 7.2 | 0.99 (0.91, 1.09) 0.902 | 44.9 | 1.02 (0.94, 1.12) 0.610 | 28.4 | 1.06 (0.95, 1.17) 0.320 | 35.9 |
NOS scores | |||||||||||
N1 | 5 | 1.04 (0.96, 1.15) 0.336 | 0.0 | 1.10 (0.95, 1.27) 0.220 | 0.0 | 0.96 (0.84, 1.09) 0.502 | 68.6 | 1.00 (0.88, 1.13) 0.968 | 49.0 | 1.10 (0.98, 1.23) 0.117 | 0.0 |
N2 | 7 | 1.05 (0.93, 1.19) 0.457 | 68.2 | 1.14 (1.00, 1.31) 0.056 | 65.9 | 1.03 (0.92, 1.15) 0.644 | 0.0 | 1.06 (0.95, 1.19) 0.271 | 0.0 | 1.08 (0.85, 1.37) 0.550 | 78.6 |
Sample size | |||||||||||
S1 | 1 | 0.93 (0.73, 1.18) 0.545 | 0.88 (0.54, 1.43) 0.602 | 1.11 (0.72, 1.72) 0.625 | 1.02 (0.68, 1.54) 0.914 | 0.82 (0.56, 1.19) 0.295 | |||||
S2 | 11 | 1.05 (0.98, 1.13) 0.205 | 47.4 | 1.13 (1.02, 1.26) 0.017 | 42.9 | 0.99 (0.91, 1.08) 0.845 | 39.1 | 1.04 (0.95, 1.13) 0.424 | 27.1 | 1.11 (0.96, 1.28) 0.146 | 65.8 |
Cancer type | |||||||||||
BLC | 2 | 1.07 (0.96, 1.19) 0.230 | 0.0 | 1.18 (0.94, 1.48) 0.151 | 0.0 | 1.17 (0.95, 1.45) 0.151 | 0.0 | 1.17 (0.96, 1.43) 0.124 | 0.0 | 1.05 (0.89, 1.22) 0.574 | 0.0 |
HCC | 3 | 1.11 (0.84, 1.47) 0.452 | 84.9 | 1.20 (0.97, 1.48) 0.089 | 83.1 | 1.04 (0.86, 1.26) 0.711 | 44.7 | 1.10 (0.92, 1.31) 0.313 | 47.0 | 1.22 (0.73, 2.03) 0.448 | 89.2 |
rs3741216 A/T | |||||||||||
Total | 4 | 1.66 (0.87, 3.18) 0.127 | 95.9 | 1.16 (0.85, 1.56) 0.348 | 0.0 | 0.91 (0.78, 1.06) 0.236 | 0.0 | 0.95 (0.82, 1.10) 0.471 | 0.0 | 2.42 (0.66, 8.83) 0.181 | 95.7 |
Ethnicity | |||||||||||
Asian | 4 | 1.66 (0.87, 3.18) 0.127 | 95.9 | 1.16 (0.85, 1.56) 0.348 | 0.0 | 0.91 (0.78, 1.06) 0.236 | 0.0 | 0.95 (0.82, 1.10) 0.471 | 0.0 | 2.42 (0.66, 8.83) 0.181 | 95.7 |
Source of control | |||||||||||
HB | 4 | 1.66 (0.87, 3.18) 0.127 | 95.9 | 0.87 (0.64, 1.17) 0.348 | 0.0 | 0.91 (0.78, 1.06) 0.236 | 0.0 | 0.95 (0.82, 1.10) 0.471 | 0.0 | 2.42 (0.66, 8.83) 0.181 | 95.7 |
NOS scores | |||||||||||
N1 | 2 | 2.96 (0.32, 27.18) 0.336 | 1.07 (0.65, 1.75) 0.798 | 0.97 (0.62, 1.50) 0.883 | 1.00 (0.67, 1.48) 0.981 | 4.22 (0.21, 84.51) 0.347 | 98.4 | ||||
N2 | 2 | 0.99 (0.87, 1.14) 0.916 | 0.0 | 0.77 (0.52, 1.12) 0.170 | 0.0 | 1.12 (0.95, 1.32) 0.186 | 0.0 | 0.94 (0.80, 1.10) 0.444 | 0.0 | 1.35 (0.92, 1.97) 0.127 | 0.0 |
Sample size | |||||||||||
S1 | 2 | 2.96 (0.32, 27.18) 0.336 | 1.07 (0.65, 1.75) 0.798 | 0.97 (0.62, 1.50) 0.883 | 1.00 (0.67, 1.48) 0.981 | 4.22 (0.21, 84.51) 0.347 | 98.4 | ||||
S2 | 2 | 0.99 (0.87, 1.14) 0.916 | 0.0 | 0.77 (0.52, 1.12) 0.170 | 0.0 | 1.12 (0.95, 1.32) 0.186 | 0.0 | 0.94 (0.80, 1.10) 0.444 | 0.0 | 1.35 (0.92, 1.97) 0.127 | 0.0 |
Cancer type | |||||||||||
GC | 2 | 1.01 (0.84, 1.21) 0.944 | 0.0 | 1.09 (0.72, 1.64) 0.697 | 4.7 | 0.97 (0.75, 1.24) 0.779 | 0.0 | 0.99 (0.78, 1.25) 0.941 | 0.0 | 1.08 (0.65, 1.70) 0.748 | 22.9 |
Correlation between rs217727 G/A polymorphism and cancer risk
Correlation between rs2839698 G/A polymorphism and cancer risk
Correlation between rs3741219 A/G polymorphism and cancer risk
Correlation between rs3024270 C/G polymorphism and cancer risk
Correlation between rs3741216 A/T polymorphism and cancer risk
FPRP results
Prior probability | |||||||||
---|---|---|---|---|---|---|---|---|---|
SNP | Genetic model | OR (95% CI) | P | Power | 0.25 | 0.1 | 0.01 | 0.001 | 0.0001 |
rs2107425 | Allele | 0.98 (0.91, 1.06) | 0.614 | 1.000 | 0.648 | 0.847 | 0.984 | 0.998 | 1.000 |
Homozygote | 1.01 (0.88, 1.17) | 0.894 | 1.000 | 0.729 | 0.890 | 0.989 | 0.999 | 1.000 | |
Heterozygote | 0.96 (0.85, 1.07) | 0.461 | 1.000 | 0.580 | 0.806 | 0.979 | 0.998 | 1.000 | |
Dominant | 0.97 (0.87, 1.08) | 0.578 | 1.000 | 0.634 | 0.839 | 0.983 | 0.998 | 1.000 | |
Recessive | 0.98 (0.91, 1.06) | 0.578 | 1.000 | 0.648 | 0.847 | 0.984 | 0.998 | 1.000 | |
rs217727 | Allele | 1.06 (0.99, 1.14) | 0.116 | 1.000 | 0.259 | 0.512 | 0.920 | 0.991 | 0.999 |
Homozygote | 1.12 (0.97, 1.30) | 0.136 | 1.000 | 0.290 | 0.551 | 0.931 | 0.933 | 0.999 | |
Heterozygote | 1.07 (0.97, 1.17) | 0.138 | 1.000 | 0.292 | 0.554 | 0.932 | 0.993 | 0.999 | |
Dominant | 1.08 (0.98, 1.19) | 0.120 | 1.000 | 0.265 | 0.519 | 0.922 | 0.992 | 0.999 | |
Recessive | 1.09 (0.96, 1.24) | 0.191 | 1.000 | 0.363 | 0.631 | 0.950 | 0.995 | 0.999 | |
rs2839698 | Allele | 1.10 (1.01, 1.20) | 0.032 | 1.000 | 0.087* | 0.223 | 0.759 | 0.969 | 0.997 |
Homozygote | 1.29 (1.09, 1.52) | 0.002 | 0.964 | 0.007* | 0.021 | 0.194 | 0.709 | 0.961 | |
Heterozygote | 1.06 (0.97,1.17) | 0.247 | 1.000 | 0.426 | 0.690 | 0.961 | 0.996 | 1.000 | |
Dominant | 1.11 (1.01, 1.23) | 0.046 | 1.000 | 0.122* | 0.294 | 0.821 | 0.979 | 0.998 | |
Recessive | 1.18 (1.01, 1.39) | 0.048 | 0.998 | 0.125* | 0.300 | 0.825 | 0.979 | 0.998 | |
rs3741219 | Allele | 1.07 (0.88, 1.30) | 0.500 | 1.000 | 0.598 | 0.817 | 0.980 | 0.998 | 1.000 |
Homozygote | 1.18 (0.94, 1.48) | 0.152 | 0.981 | 0.317 | 0.583 | 0.939 | 0.994 | 0.999 | |
Heterozygote | 0.97 (0.71, 1.33) | 0.850 | 0.999 | 0.720 | 0.885 | 0.988 | 0.999 | 1.000 | |
Dominant | 1.06 (0.79, 1.41) | 0.689 | 0.991 | 0.674 | 0.861 | 0.986 | 0.999 | 1.000 | |
Recessive | 1.14 (1.01, 1.29) | 0.038 | 1.000 | 0.102* | 0.254 | 0.789 | 0.974 | 0.997 | |
rs3024270 | Allele | 1.04 (0.97, 1.12) | 0.300 | 1.000 | 0.473 | 0.729 | 0.967 | 0.997 | 1.000 |
Homozygote | 1.12 (1.01, 1.24) | 0.029 | 1.000 | 0.080* | 0.207 | 0.742 | 0.967 | 0.997 | |
Heterozygote | 1.00 (0.92, 1.09) | 0.928 | 1.000 | 0.736 | 0.893 | 0.989 | 0.999 | 1.000 | |
Dominant | 1.03 (0.95, 1.12) | 0.489 | 1.000 | 0.595 | 0.815 | 0.980 | 0.998 | 1.000 | |
Recessive | 1.09 (0.95, 1.25) | 0.228 | 1.000 | 0.406 | 0.673 | 0.958 | 0.996 | 1.000 | |
rs3741216 | Allele | 1.66 (0.87, 3.18) | 0.126 | 0.380 | 0.500 | 0.750 | 0.971 | 0.997 | 1.000 |
Homozygote | 1.16 (0.85, 1.56) | 0.773 | 0.691 | 0.731 | 0.891 | 0.989 | 0.999 | 1.000 | |
Heterozygote | 0.91 (0.78, 1.06) | 0.226 | 1.000 | 0.404 | 0.670 | 0.957 | 0.996 | 1.000 | |
Dominant | 0.95 (0.82, 1.10) | 0.493 | 1.000 | 0.597 | 0.816 | 0.980 | 0.998 | 1.000 | |
Recessive | 2.42 (0.66, 8.83) | 0.181 | 0.234 | 0.689 | 0.874 | 0.987 | 0.999 | 1.000 |
Sensitivity analysis and publication bias
Genetic model | rs217727G/A | rs2839698G/A | rs3741219T/C | rs3741216A/T | |
---|---|---|---|---|---|
Allele | OR (95%CI)
P
I2 (%)
P
(heterogeneity)
| 1.06 (1.00, 1.13) 0.071 69.8 0.000 | 1.06 (0.98, 1.15) 0.132 77.1 0.000 | 1.02 (0.84, 1.24) 0.850 89.6 0.000 | 0.99 (0.87, 1.14) 0.916 0.0 0.649 |
Homozygote | OR (95%CI)
P
I2 (%)
P
(heterogeneity)
| 1.13 (1.00, 1.28) 0.053 60.6 0.000 | 1.21 (1.04, 1.41) 0.014 66.2 0.000 | 1.14 (0.91, 1.43) 0.269 61.6 0.000 | 0.31 (0.89, 1.92) 0.170 0.0 0.678 |
Heterozygote | OR (95%CI)
P
I2 (%)
P
(heterogeneity)
| 1.04 (0.95, 1.14) 0.369 68.2 0.000 | 1.04 (0.95, 1.13) 0.392 61.3 0.000 | 0.96 (0.70, 1.32) 0.795 92.7 0.000 | 0.89 (0.76, 1.06) 0.186 0.0 0.737 |
Dominant | OR (95%CI)
P
I2 (%)
P
(heterogeneity)
| 1.67 (0.98, 1.17) 0.157 70.3 0.000 | 1.07 (0.98, 1.17) 0.124 66.6 0.000 | 1.00 (0.75, 1.35) 0.978 92.4 0.000 | 0.94 (0.80, 1.10) 0.444 0.0 0.681 |
Recessive | OR (95%CI)
P
I2 (%)
P
(heterogeneity)
| 1.11 (0.99, 1.24) 0.073 59.2 0.000 | 1.12 (0.96, 1.32) 0.147 72.9 0.000 | 1.12 (0.99, 1.27) 0.074 0.0 0.763 | 1.35 (0.92, 1.97) 0.127 0.0 0.708 |
Variables | Allelic | Homozygous | Heterozygous | Dominant | Recessive | ||||
---|---|---|---|---|---|---|---|---|---|
P B PE | P B PE | P B PE | P B PE | P B PE | |||||
rs2107425C/T | 0.360 0.336 | 0.583 0.436 | 0.246 0.286 | 0.300 0.287 | 0.583 0.532 | ||||
rs217727G/A | 0.454 0.515 | 0.592 0.494 | 0.475 0.489 | 0.354 0.445 | 0.748 0.540 | ||||
rs2839698G/A | 0.252 0.317 | 0.315 0.393 | 0.338 0.351 | 0.388 0.363 | 0.252 0.448 | ||||
rs3741219A/G | 0.371 0.404 | 0.371 0.265 | 0.592 0.571 | 0.371 0.346 | 0.474 0.311 | ||||
rs3024270C/G | 1.000 0.867 | 1.000 0.875 | 0.876 0.861 | 0.876 0.775 | 0.533 0.791 | ||||
rs3741216A/T | 0.308 0.170 | 1.000 0.200 | 1.000 0.815 | 1.000 0.815 | 1.000 0.803 |